Emerging Therapies in Hemophilia: Improving Equitable Access to Care

Magdalena Lewandowska,1 Sonia Nasr,2 Amy D Shapiro1 1Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, USA; 2GLOVAL LLC, Broomfield, Colorado, USACorrespondence: Amy D Shapiro, MD. Indiana Hemophilia and Thrombosis Center, Inc., 8326 Naab Road, Indianapolis, IN, 46260, USA, Em...

Full description

Saved in:
Bibliographic Details
Main Authors: Lewandowska M, Nasr S, Shapiro AD
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:Journal of Blood Medicine
Subjects:
Online Access:https://www.dovepress.com/emerging-therapies-in-hemophilia-improving-equitable-access-to-care-peer-reviewed-fulltext-article-JBM
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850192480248528896
author Lewandowska M
Nasr S
Shapiro AD
author_facet Lewandowska M
Nasr S
Shapiro AD
author_sort Lewandowska M
collection DOAJ
description Magdalena Lewandowska,1 Sonia Nasr,2 Amy D Shapiro1 1Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, USA; 2GLOVAL LLC, Broomfield, Colorado, USACorrespondence: Amy D Shapiro, MD. Indiana Hemophilia and Thrombosis Center, Inc., 8326 Naab Road, Indianapolis, IN, 46260, USA, Email ashapiro@ihtc.orgAbstract: In recent years, gene therapy and bio-engineered hemostatic molecules have revolutionized treatment for people with hemophilia. These innovative therapies aim to decrease treatment burden and improve patient quality of life. Additional novel therapies, including next-generation mimetics and agents that rebalance hemostasis, are currently being evaluated in clinical trials. Technological advances such as point-of-care musculoskeletal ultrasound and artificial intelligence may improve patient diagnostic and treatment outcomes. However, for the majority of patients with hemophilia worldwide, diagnosis and effective treatment are inaccessible. Achieving health equity for all hemophilia patients requires improved identification of barriers to optimal care, including socioeconomic status, race/ethnicity, gender, disease severity, inhibitor status, age, and use of Hemophilia Treatment Centers. Access to novel hemophilia therapies should be ensured for all patients. Approaches to improving equity include a decision-making partnership between the patient and clinician, stakeholder engagement, and pharmaceutical industry support. The development of novel hemophilia therapies should be leveraged with a patient-centered care approach to improve health equity for all patients.Keywords: gene therapy, non-factor therapy, artificial intelligence, point-of-care musculoskeletal ultrasound, health equity
format Article
id doaj-art-337c4e00c2a24cf9be4c7612bd404a2d
institution OA Journals
issn 1179-2736
language English
publishDate 2025-02-01
publisher Dove Medical Press
record_format Article
series Journal of Blood Medicine
spelling doaj-art-337c4e00c2a24cf9be4c7612bd404a2d2025-08-20T02:14:31ZengDove Medical PressJournal of Blood Medicine1179-27362025-02-01Volume 1695115100399Emerging Therapies in Hemophilia: Improving Equitable Access to CareLewandowska MNasr SShapiro ADMagdalena Lewandowska,1 Sonia Nasr,2 Amy D Shapiro1 1Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, USA; 2GLOVAL LLC, Broomfield, Colorado, USACorrespondence: Amy D Shapiro, MD. Indiana Hemophilia and Thrombosis Center, Inc., 8326 Naab Road, Indianapolis, IN, 46260, USA, Email ashapiro@ihtc.orgAbstract: In recent years, gene therapy and bio-engineered hemostatic molecules have revolutionized treatment for people with hemophilia. These innovative therapies aim to decrease treatment burden and improve patient quality of life. Additional novel therapies, including next-generation mimetics and agents that rebalance hemostasis, are currently being evaluated in clinical trials. Technological advances such as point-of-care musculoskeletal ultrasound and artificial intelligence may improve patient diagnostic and treatment outcomes. However, for the majority of patients with hemophilia worldwide, diagnosis and effective treatment are inaccessible. Achieving health equity for all hemophilia patients requires improved identification of barriers to optimal care, including socioeconomic status, race/ethnicity, gender, disease severity, inhibitor status, age, and use of Hemophilia Treatment Centers. Access to novel hemophilia therapies should be ensured for all patients. Approaches to improving equity include a decision-making partnership between the patient and clinician, stakeholder engagement, and pharmaceutical industry support. The development of novel hemophilia therapies should be leveraged with a patient-centered care approach to improve health equity for all patients.Keywords: gene therapy, non-factor therapy, artificial intelligence, point-of-care musculoskeletal ultrasound, health equityhttps://www.dovepress.com/emerging-therapies-in-hemophilia-improving-equitable-access-to-care-peer-reviewed-fulltext-article-JBMgene therapynon-factor therapyartificial intelligencepoint-of-care musculoskeletal ultrasoundhealth equity
spellingShingle Lewandowska M
Nasr S
Shapiro AD
Emerging Therapies in Hemophilia: Improving Equitable Access to Care
Journal of Blood Medicine
gene therapy
non-factor therapy
artificial intelligence
point-of-care musculoskeletal ultrasound
health equity
title Emerging Therapies in Hemophilia: Improving Equitable Access to Care
title_full Emerging Therapies in Hemophilia: Improving Equitable Access to Care
title_fullStr Emerging Therapies in Hemophilia: Improving Equitable Access to Care
title_full_unstemmed Emerging Therapies in Hemophilia: Improving Equitable Access to Care
title_short Emerging Therapies in Hemophilia: Improving Equitable Access to Care
title_sort emerging therapies in hemophilia improving equitable access to care
topic gene therapy
non-factor therapy
artificial intelligence
point-of-care musculoskeletal ultrasound
health equity
url https://www.dovepress.com/emerging-therapies-in-hemophilia-improving-equitable-access-to-care-peer-reviewed-fulltext-article-JBM
work_keys_str_mv AT lewandowskam emergingtherapiesinhemophiliaimprovingequitableaccesstocare
AT nasrs emergingtherapiesinhemophiliaimprovingequitableaccesstocare
AT shapiroad emergingtherapiesinhemophiliaimprovingequitableaccesstocare